ArriVent projects topline phase 3 FURVENT data for firmonertinib in early 2026

ArriVent BioPharma, Inc.

Topline firmonertinib monotherapy data from pivotal Phase 3 FURVENT study in 1L NSCLC EGFR exon20ins projected early 2026.
Primary endpoint is progression-free survival by blinded independent central review per RECIST 1.1.
Enrollment in the global FURVENT study completed in Q1 2025.
Firmonertinib previously received FDA Breakthrough Therapy Designation for this patient population.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.